Delivery Order SPE2DB22D1202-SPE2DB25FVKK7
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $1,117.35 to AmerisourceBergen Drug Corp for Atovaquone-Proguanil 250-100mg tablets (100 count) with an ultimate completion date of August 25, 2025. This firm fixed price, non-set-aside contract was awarded on August 22, 2025, with performance at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The antimalarial medication will support federal medical supply requirements, likely for military personnel...
- The Defense Logistics Agency awarded a delivery order valued at $10,096.69 to AmerisourceBergen Drug Corp for the supply of Atovaquone-Proguanil 250-100 100 tablets, with an ultimate completion date of June 2, 2025. This competitively awarded, firm fixed-price contract involves no set-aside designation and will be performed at the contractor's facility in Conshohocken, Pennsylvania. Atovaquone-Proguanil is an antimalarial medication commonly used for malaria prophylaxis and treatment in military...
- The Defense Logistics Agency awarded a delivery order valued at $25,275.80 to AmerisourceBergen Drug Corp for the supply of Atovaquone-Proguanil 250-100 tablets (100-count units) with a completion date of June 2, 2025. This competitively awarded, firm fixed-price contract contains no set-aside designation and represents a child order under AmerisourceBergen's larger pharmaceutical supply vehicle with DLA. The pharmaceutical product will be delivered to the vendor's corporate office location in...
- The Defense Logistics Agency awarded a delivery order valued at $7,718.44 to AmerisourceBergen Drug Corp on August 26, 2025, for the supply of Atovaquone-Proguanil 250-100mg in quantities of 100 tablets. This competitively awarded, firm fixed-price contract is classified as a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.99 billion global pharmaceutical support vehicle running through December 2026. The work will be...
- The Defense Logistics Agency awarded a delivery order valued at $9,402.12 to AmerisourceBergen Drug Corp on May 6, 2025, for the supply of Atovaquone-Proguanil 250-100 mg tablets (100 count). This is a firm fixed-price, non-set-aside competitive award with a completion date of May 7, 2025. The place of performance is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. Atovaquone-Proguanil is an antimalarial medication commonly used for malaria prophylaxis and treatment,...
- The Defense Logistics Agency awarded a delivery order valued at $1,119.30 to AmerisourceBergen Drug Corp for Atovaquone-Proguanil 250-100, 100 tablets, with an ultimate completion date of June 5, 2025. This is a firm fixed-price delivery order with no set-aside designation, competitively awarded under AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.99 billion global pharmaceutical support vehicle running through December 2026. The product...
- The Defense Logistics Agency awarded a delivery order valued at $1,586.54 to AmerisourceBergen Drug Corp for the supply of Atovaquone-Proguanil 250-100 tablets in a quantity of 100 units. This is a firm fixed price, competitively awarded delivery order with an ultimate completion date of September 11, 2025, and represents a non-set-aside procurement. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location. The product being...
- The U.S. Defense Logistics Agency's Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on August 14, 2025, for the supply of Atovaquone-Proguanil 250-100mg tablets in a quantity of 100 units. This is a firm fixed-price delivery order valued at $10,073.70 with an ultimate completion date of August 15, 2025. The contract is not set-aside and was competitively awarded. The pharmaceutical products will be delivered to Conshohocken, Pennsylvania, the corporate headquarters...
- The Defense Logistics Agency awarded a delivery order valued at $6,844.74 to AmerisourceBergen Drug Corp for Atovaquone-Proguanil 250-100 tablets (100 count) on October 16, 2025, with an ultimate completion date of October 17, 2025. This firm fixed-price delivery order was competitively awarded without set-aside designation to the pharmaceutical distributor's Corporate Office location in Conshohocken, Pennsylvania. The award represents a small-value transaction under AmerisourceBergen Drug...
- The Defense Logistics Agency awarded a delivery order valued at $8,129.27 to AmerisourceBergen Drug Corp for the supply of Atovaquone-Proguanil 250-100mg in quantities of 100 units. The contract, issued on July 14, 2025, with completion targeted for July 15, 2025, utilizes firm fixed pricing with no set-aside designation, indicating competitive award. Performance will be executed at AmerisourceBergen's Conshohocken, Pennsylvania location. This delivery order is a child contract under...
- SPE2DB22D1202Indefinite Delivery Contract
- SPE2DB22D1202-SPE2DB25FVKK7Delivery Order
The Defense Logistics Agency awarded a delivery order valued at $16,117.92 to AmerisourceBergen Drug Corp for Atovaquone-Proguanil 250-100 mg tablets (100 count) with a completion date of September 8, 2025. This competitively awarded, firm fixed-price delivery order leverages AmerisourceBergen's Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.99 billion global pharmaceutical support vehicle running through December 2026. The contract requires delivery to the contractor's corporate office location in Conshohocken, Pennsylvania, where AmerisourceBergen operates as a major pharmaceutical distributor serving military and federal healthcare systems. Atovaquone-Proguanil is an antimalarial medication commonly used for malaria prophylaxis and treatment within military medical readiness programs and Department of Defense healthcare operations. This delivery order represents a standard transactional award under AmerisourceBergen's broader pharmaceutical supply agreement, reflecting the company's established role as a critical vendor for federal medical procurement. No set-aside designation was applied to this award, indicating it was awarded through open competitive procedures consistent with AmerisourceBergen's demonstrated federal contracting capabilities across the Defense Health Agency and other government healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $16.1k | 9/5/25 |